Einstein-Invented Compound Now Being Tested in COVID-19 Clinical Trial: Yeshiva University
April 29, 2020
April 29, 2020
BRONX, New York, April 29 -- Yeshiva University's Albert Einstein College of Medicine issued the following news release:
A compound originally discovered by Albert Einstein College of Medicine's Vern Schramm, Ph.D., is being evaluated by BioCryst Pharmaceuticals, Inc., in Brazil as a treatment for COVID-19 patients. The randomized, double-blind, placebo-controlled trial is funded by the National Institute of Allergy and Infectious Diseases.
The compound, BCX4430, result . . .
A compound originally discovered by Albert Einstein College of Medicine's Vern Schramm, Ph.D., is being evaluated by BioCryst Pharmaceuticals, Inc., in Brazil as a treatment for COVID-19 patients. The randomized, double-blind, placebo-controlled trial is funded by the National Institute of Allergy and Infectious Diseases.
The compound, BCX4430, result . . .